S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.19
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
18.55
+1.87
+11.21%
TNGX · Tango Therapeutics, Inc.
NASDAQ NMS - GLOBAL MARKET - Real Time Price • USD
Tango Therapeutics Inc (TNGX)
NASDAQ NMS - GLOBAL MARKET
Biotechnology
$26.99
+1.72
(+6.81%)
● At close: October 21 at 4:00:00 PM EDT
DAY'S RANGE
$26.99
$25.35
$27.48
52-WEEK RANGE
$26.99
$6.69
$34.39
What's happening
- TNGX is up 6.81% today, trading at $26.99. — Live quote
- Volume today (441,201) is well below its 3-month average of 3,292,540. (Finnhub fundamentals)
- Reports earnings on 2026-11-10, 19 days away. (Finnhub earnings calendar)
- Last quarter's EPS missed estimates: $-0.37 actual vs. $-0.32 estimated (-13.9%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 8
Buy 8
Hold 2
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (18 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
TNGX
+184.99%
vs S&P 500
+172.21%
1-YEAR RETURN
TNGX
+175.96%
vs S&P 500
+161.40%
6-MONTH RETURN
TNGX
+0.84%
3-MONTH RETURN
TNGX
-12.99%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-0.37
Est. $-0.32
MISS -13.9%
2026-04-26 (Q1 2026)
$-0.32
Est. $-0.32
MISS -0.1%
2026-01-26 (Q4 2025)
$-0.29
Est. $-0.33
BEAT +11.2%
2025-10-26 (Q3 2025)
$0.14
Est. $-0.05
BEAT +360.2%
Valuation Measures & Ratios
Enterprise Value4$4.20B
Forward P/E5—
PEG Ratio6—
Price / Sales (TTM1)68.41
Price / Book74.95
EV4 / Revenue63.21
EV4 / EBITDA—
Profit Margin-151.15%
Operating Margin-165.91%
Return on Equity (ROE8)-25.74%
Return on Assets (ROA9)-23.36%
Avg Volume (3M)3,292,540
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $4.67B | $2.98B | $1.03B | $568.9M | $151.2M |
| P/E | -37.75 | -27.47 | -11.15 | -4.26 | -1.14 |
| Price/Sales | 82.01 | 47.72 | 13.87 | 14.20 | 3.49 |
| Price/Book | 4.56 | 7.60 | 6.41 | 4.22 | 0.91 |
| EV/Revenue | 75.95 | 45.19 | 13.08 | 13.22 | 2.14 |
| ROE | -12.09% | -27.68% | -57.50% | -98.88% | -79.46% |
| ROA | -11.53% | -24.86% | -43.79% | -56.10% | -48.31% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short44,500,110
Change from Prior Settlement+6.27%
% of Float—
Days to Cover (Short Ratio)12.54
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Trailing 52-week price return is +176.0%. Finnhub market metrics ↗
Potential concerns
- Net profit margin is -151.2%. Finnhub fundamentals ↗
- Latest SEC filing is Form 4, filed 2026-10-05; review it for current changes and risks. SEC EDGAR ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on TNGX
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $53.8M | $3.2M | $5.4M | $11.6M | $19.9M | $6.5M |
| Operating income | -$59.8M | -$48.8M | $14.1M | -$41.0M | -$42.5M | -$32.9M | -$29.6M | -$42.3M |
| Net income | -$55.3M | -$45.5M | $15.9M | -$38.9M | -$39.9M | -$29.2M | -$25.6M | -$37.9M |
| EPS (diluted) | $-0.37 | $-0.32 | $0.13 | $-0.35 | $-0.36 | $-0.27 | $-0.24 | $-0.35 |
| EPS (basic) | $-0.37 | $-0.32 | $0.14 | $-0.35 | $-0.36 | $-0.27 | $-0.24 | $-0.35 |
| Operating margin | — | — | $26 | -$1.3K | -$789 | -$283 | -$149 | -$653 |
| Net margin | — | — | $30 | -$1.2K | -$740 | -$251 | -$129 | -$586 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $1.07B | $435.8M | $398.7M | $210.1M | $237.9M | $274.3M | $316.5M | $352.4M |
| Total liabilities | $49.3M | $44.3M | $52.5M | $50.1M | $102.9M | $107.5M | $117.0M | $123.2M |
| Stockholders' equity | $1.02B | $391.5M | $346.2M | $160.0M | $135.0M | $166.8M | $199.5M | $229.2M |
| Total current assets | $1.03B | $392.3M | $353.8M | $163.8M | $190.1M | $224.9M | $266.3M | $300.8M |
| Total current liabilities | $20.3M | $14.3M | $21.7M | $18.4M | $40.0M | $35.9M | $38.2M | $37.6M |
| Cash & equivalents | $345.6M | $157.8M | $112.3M | $58.3M | $39.3M | $58.4M | $69.5M | $53.1M |
| Marketable securities (current) | $668.4M | $222.0M | $230.9M | $94.5M | $141.5M | $158.3M | $188.4M | $240.1M |
| Accounts receivable | — | — | — | — | — | — | — | — |
| Property, plant & equipment | $6.1M | $6.4M | $6.9M | $7.3M | $7.8M | $7.5M | $8.1M | $8.6M |
| Other non-current assets | $312.0K | $293.0K | $303.0K | $290.0K | $310.0K | $1.0K | $4.0K | $13.0K |
| Accounts payable | $1.8M | $2.4M | $1.2M | $2.2M | $2.6M | $3.2M | $1.6M | $4.1M |
| Accrued liabilities | — | — | — | — | — | — | — | — |
| Deferred revenue (current) | — | — | $0 | $0 | $23.4M | $19.5M | $17.6M | $15.6M |
| Other non-current liabilities | — | — | — | — | — | — | — | — |
| Common stock & paid-in capital | $168.0K | $144.0K | $136.0K | $112.0K | $111.0K | $108.0K | $108.0K | $107.0K |
| Retained earnings | -$704.0M | -$648.7M | -$603.2M | -$564.4M | -$580.3M | -$541.4M | -$501.6M | -$463.9M |
| Accumulated other comprehensive income (loss) | -$633.0K | -$115.0K | $224.0K | $121.0K | $94.0K | $194.0K | $336.0K | $750.0K |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$38.9M | -$44.4M | -$29.7M | -$31.0M | -$36.5M | -$41.7M | -$36.6M | -$33.4M |
| Investing cash flow | -$446.0M | $9.6M | -$135.7M | $47.5M | $16.8M | $30.6M | $52.1M | $32.6M |
| Financing cash flow | $672.6M | $79.8M | $219.4M | $2.5M | $581.0K | $2.0K | $969.0K | $2.4M |
| Free cash flow | -$38.8M | -$44.4M | -$29.9M | -$31.1M | -$37.1M | -$41.7M | -$36.8M | -$33.5M |
| Capital expenditures | -$20.0K | -$2.0K | $222.0K | $151.0K | $624.0K | $51.0K | $124.0K | $115.0K |
| Share-based compensation | $16.9M | $10.8M | $6.0M | $6.6M | $6.6M | $7.3M | $7.5M | $7.2M |
| Deferred income taxes | — | — | — | — | — | — | — | — |
| Change in accounts receivable | — | — | — | — | — | — | — | — |
| Change in accounts payable | — | — | — | — | — | — | — | — |
| Purchases of investments | $519.1M | $54.4M | $175.0M | $18.3M | $23.9M | $47.2M | $32.5M | $39.5M |
| Other investing activities | — | — | — | — | — | — | — | — |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $62.4M | $42.1M | $36.5M | $24.9M | $37.0M |
| Operating income | -$111.3M | -$145.6M | -$114.2M | -$111.1M | -$58.2M |
| Net income | -$101.6M | -$130.3M | -$101.7M | -$108.2M | -$58.2M |
| EPS (diluted) | $-0.87 | $-1.19 | $-1.08 | $-1.23 | $-0.94 |
| EPS (basic) | $-0.87 | $-1.19 | $-1.08 | $-1.23 | $-0.94 |
| Operating margin | -$178 | -$346 | -$313 | -$447 | -$157 |
| Net margin | -$163 | -$310 | -$279 | -$435 | -$157 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $398.7M | $316.5M | $402.6M | $436.5M | $500.2M |
| Total liabilities | $52.5M | $117.0M | $149.5M | $187.0M | $155.4M |
| Stockholders' equity | $346.2M | $199.5M | $253.1M | $249.5M | $344.7M |
| Total current assets | $353.8M | $266.3M | $346.5M | $375.3M | $492.3M |
| Total current liabilities | $21.7M | $38.2M | $45.9M | $55.5M | $40.7M |
| Cash & equivalents | $112.3M | $69.5M | $66.4M | $60.0M | $142.7M |
| Marketable securities (current) | $230.9M | $188.4M | $270.5M | $306.2M | $342.5M |
| Accounts receivable | — | — | — | $2.0M | $2.0M |
| Property, plant & equipment | $6.9M | $8.1M | $9.9M | $10.9M | $4.8M |
| Other non-current assets | $303.0K | $4.0K | $46.0K | $5.0K | $19.0K |
| Accounts payable | $1.2M | $1.6M | $2.8M | $4.5M | $3.2M |
| Accrued liabilities | — | — | — | — | — |
| Deferred revenue (current) | $0 | $17.6M | $25.7M | $31.8M | $26.0M |
| Other non-current liabilities | — | — | — | — | — |
| Common stock & paid-in capital | $136.0K | $108.0K | $102.0K | $88.0K | $88.0K |
| Retained earnings | -$603.2M | -$501.6M | -$371.3M | -$269.5M | -$161.3M |
| Accumulated other comprehensive income (loss) | $224.0K | $336.0K | $186.0K | -$3.7M | -$765.0K |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$138.9M | -$131.5M | -$118.0M | -$109.1M | -$59.5M |
| Investing cash flow | -$40.9M | $86.1M | $41.4M | $26.4M | -$183.4M |
| Financing cash flow | $222.5M | $47.7M | $82.4M | $1.6M | $357.3M |
| Free cash flow | -$139.9M | -$132.3M | -$119.5M | -$116.8M | -$61.4M |
| Capital expenditures | $1.0M | $754.0K | $1.5M | $7.7M | $1.8M |
| Share-based compensation | $26.4M | $28.9M | $19.1M | $14.2M | $7.8M |
| Change in accounts receivable | — | — | -$2.0M | — | — |
| Purchases of investments | $264.5M | $240.9M | $310.6M | $208.5M | $372.4M |
| Other investing activities | — | — | — | — | — |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding TNGX as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Source: Business Quant SEC Form 13F · report period 2026-06-30 · 30 filers
Held by These Filers113.8%
Shares Outstanding149,875,939
| Filer | Shares | Value | % Out | Qtr Change | Filed |
|---|---|---|---|---|---|
| RTW INVESTMENTS, LP | 13,900,620 | $434.5M | 9.27% | +4.5% | 2026-08-14 |
| BlackRock, Inc. | 12,438,444 | $388.8M | 8.30% | +42.2% | 2026-08-07 |
| FMR LLC | 12,333,339 | $385.5M | 8.23% | +24.5% | 2026-08-13 |
| FARALLON CAPITAL MANAGEMENT, L.L.C. | 12,277,000 | $383.8M | 8.19% | +35.0% | 2026-08-14 |
| Boxer Capital Management, LLC | 10,876,219 | $340.0M | 7.26% | +0.0% | 2026-08-14 |
| Goldman Sachs Group Inc | 9,980,620 | $312.0M | 6.66% | +96.6% | 2026-08-14 |
| TCG Crossover Management, LLC | 9,081,201 | $283.9M | 6.06% | -13.8% | 2026-08-12 |
| TRV GP IV, LLC | 6,374,574 | $120.2M | 4.25% | +0.0% | 2026-08-07 |
| Paradigm Biocapital Advisors LP | 6,357,523 | $198.7M | 4.24% | +58.6% | 2026-08-14 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 6,348,827 | $198.5K | 4.24% | +613.8% | 2026-08-14 |
| Siren, L.L.C. | 6,179,364 | $193.2M | 4.12% | +9.2% | 2026-08-13 |
| State Street Corp | 5,979,806 | $186.9M | 3.99% | +28.5% | 2026-08-07 |
| VANGUARD CAPITAL MANAGEMENT LLC | 5,957,348 | $186.2M | 3.97% | +15.4% | 2026-06-30 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 5,600,000 | $175.1M | 3.74% | -56.3% | 2026-08-14 |
| Jupiter Topco LLC | 5,056,352 | $158.0M | 3.37% | +0.0% | 2026-08-14 |
| Deep Track Capital, LP | 4,200,000 | $131.3M | 2.80% | +52.7% | 2026-08-14 |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 4,190,611 | $131.0M | 2.80% | +1.1% | 2026-08-14 |
| Woodline Partners LP | 4,000,567 | $125.1M | 2.67% | -50.0% | 2026-08-14 |
| GEODE CAPITAL MANAGEMENT, LLC | 3,742,791 | $117.0M | 2.50% | +39.9% | 2026-08-12 |
| PERCEPTIVE ADVISORS LLC | 3,377,000 | $105.6M | 2.25% | +317.9% | 2026-08-14 |
| Seven Fleet Capital Management LP | 3,228,144 | $95.7M | 2.15% | +543.0% | 2026-08-14 |
| Logos Global Management LP | 2,850,000 | $89.1M | 1.90% | -5.0% | 2026-08-14 |
| Caligan Partners LP | 2,500,103 | $78.2M | 1.67% | +3.8% | 2026-08-14 |
| Holocene Advisors, LP | 2,410,939 | $75.4M | 1.61% | -38.7% | 2026-08-14 |
| Commodore Capital LP | 2,250,000 | $70.3M | 1.50% | +0.0% | 2026-08-14 |
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2026-01-02 to 2026-10-01
Recent transactions
- Insiders have net sold 170,200 shares over the last 182 days, across 0 purchases and 14 sales.
- Most recent: Crystal Adam (President, R&D) — Option exercise of 27,000 shares on 2026-10-01.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)170,200 sh(14 txns)
Net Shares-170,200
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Crystal Adam | President, R&D | Option exercise | 2026-10-01 | 27,000 |
| Newcomb Jessica | Principal Accounting Officer | Open market sale | 2026-09-22 | 700 |
| Azelby Robert | Reporting person | Grant / award | 2026-06-19 | 5,740 |
| Ketchum John B | Reporting person | Grant / award | 2026-06-05 | 4,000 |
| Calhoun Lesley Ann | Reporting person | Grant / award | 2026-06-05 | 4,000 |
| Rothenberg Mace | Reporting person | Grant / award | 2026-06-05 | 4,000 |
| Lee Sung | Reporting person | Grant / award | 2026-06-05 | 570 |
| Gall Matthew | Chief Financial Officer | Grant / award | 2026-05-01 | 40,000 |
| Beckman Daniella | Chief Financial Officer | Open market sale | 2026-02-03 | 10,204 |
| Weber Barbara | Director, Executive Chair | Open market sale | 2026-02-03 | 30,186 |
| Peters Malte | President & CEO | Grant / award | 2026-01-08 | 350,000 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-10-01 | Crystal Adam | President, R&D | Option exercise | 27,000 | $5.20 |
| 2026-10-01 | Crystal Adam | President, R&D | Open market sale | 26,400 | $24.45 |
| 2026-10-01 | Crystal Adam | President, R&D | Open market sale | 600 | $25.32 |
| 2026-09-22 | Newcomb Jessica | Principal Accounting Officer | Open market sale | 700 | $22.80 |
| 2026-09-22 | Newcomb Jessica | Principal Accounting Officer | Open market sale | 5,100 | $23.97 |
| 2026-09-22 | Newcomb Jessica | Principal Accounting Officer | Open market sale | 2,400 | $25.17 |
| 2026-09-01 | Crystal Adam | President, R&D | Option exercise | 27,000 | $5.20 |
| 2026-09-01 | Crystal Adam | President, R&D | Open market sale | 27,000 | $22.37 |
| 2026-08-03 | Crystal Adam | President, R&D | Option exercise | 27,000 | $5.20 |
| 2026-08-03 | Crystal Adam | President, R&D | Open market sale | 5,267 | $26.79 |
| 2026-08-03 | Crystal Adam | President, R&D | Open market sale | 21,733 | $27.35 |
| 2026-07-01 | Crystal Adam | President, R&D | Option exercise | 27,000 | $5.20 |
| 2026-07-01 | Crystal Adam | President, R&D | Open market sale | 19,629 | $29.34 |
| 2026-07-01 | Crystal Adam | President, R&D | Open market sale | 7,371 | $30.25 |
| 2026-06-19 | Azelby Robert | Reporting person | Grant / award | 5,740 | $0.00 |
| 2026-06-05 | Ketchum John B | Reporting person | Grant / award | 4,000 | $0.00 |
| 2026-06-05 | Calhoun Lesley Ann | Reporting person | Grant / award | 4,000 | $0.00 |
| 2026-06-05 | Rothenberg Mace | Reporting person | Grant / award | 4,000 | $0.00 |
| 2026-06-05 | Lee Sung | Reporting person | Grant / award | 570 | $0.00 |
| 2026-06-01 | Crystal Adam | President, R&D | Option exercise | 27,000 | $5.20 |
| 2026-06-01 | Crystal Adam | President, R&D | Open market sale | 6,140 | $22.25 |
| 2026-06-01 | Crystal Adam | President, R&D | Open market sale | 20,860 | $23.06 |
| 2026-05-01 | Crystal Adam | President, R&D | Option exercise | 27,000 | $5.20 |
| 2026-05-01 | Crystal Adam | President, R&D | Open market sale | 25,900 | $21.19 |
| 2026-05-01 | Crystal Adam | President, R&D | Open market sale | 1,100 | $22.00 |
| 2026-05-01 | Gall Matthew | Chief Financial Officer | Grant / award | 40,000 | $0.00 |
| 2026-04-29 | Lee Sung | Reporting person | Grant / award | 12,300 | $0.00 |
| 2026-04-15 | Crystal Adam | President, R&D | Option exercise | 38,460 | $5.20 |
| 2026-04-15 | Crystal Adam | President, R&D | Open market sale | 38,460 | $25.00 |
| 2026-04-01 | Crystal Adam | President, R&D | Option exercise | 27,000 | $5.20 |
| 2026-04-01 | Crystal Adam | President, R&D | Open market sale | 27,000 | $21.20 |
| 2026-03-25 | Crystal Adam | President, R&D | Option exercise | 12,000 | $5.20 |
| 2026-03-25 | Crystal Adam | President, R&D | Open market sale | 12,000 | $20.11 |
| 2026-03-05 | Crystal Adam | President, R&D | Open market sale | 20,251 | $15.00 |
| 2026-02-25 | Crystal Adam | President, R&D | Open market sale | 54,345 | $12.77 |
| 2026-02-03 | Beckman Daniella | Chief Financial Officer | Open market sale | 10,204 | $12.26 |
| 2026-02-03 | Beckman Daniella | Chief Financial Officer | Open market sale | 113 | $12.90 |
| 2026-02-03 | Weber Barbara | Director, Executive Chair | Open market sale | 30,186 | $12.26 |
| 2026-02-03 | Weber Barbara | Director, Executive Chair | Open market sale | 333 | $12.90 |
| 2026-02-03 | Crystal Adam | President, R&D | Open market sale | 18,251 | $12.26 |
| 2026-02-03 | Crystal Adam | President, R&D | Open market sale | 201 | $12.90 |
| 2026-02-02 | Beckman Daniella | Chief Financial Officer | Grant / award | 44,330 | $0.00 |
| 2026-02-02 | Weber Barbara | Director, Executive Chair | Grant / award | 37,522 | $0.00 |
| 2026-02-02 | Crystal Adam | President, R&D | Grant / award | 47,460 | $0.00 |
| 2026-01-08 | Peters Malte | President & CEO | Grant / award | 350,000 | $0.00 |
| 2026-01-02 | Lee Sung | Reporting person | Grant / award | 10,000 | $0.00 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 07:59 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-05 | 4 | 2026-10-01 | View on SEC.gov → |
| 2026-09-24 | 4 | 2026-09-22 | View on SEC.gov → |
| 2026-09-03 | 4 | 2026-09-01 | View on SEC.gov → |
| 2026-08-11 | 8-K | 2026-08-11 | View on SEC.gov → |
| 2026-08-11 | 8-K | 2026-08-11 | View on SEC.gov → |
| 2026-08-11 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-06 | 8-K | 2026-07-31 | View on SEC.gov → |
| 2026-08-05 | 4 | 2026-08-03 | View on SEC.gov → |
| 2026-07-02 | 4 | 2026-07-01 | View on SEC.gov → |
| 2026-06-23 | 4 | 2026-06-19 | View on SEC.gov → |
| 2026-06-23 | 8-K | 2026-06-19 | View on SEC.gov → |
| 2026-06-10 | 8-K | 2026-06-09 | View on SEC.gov → |
Recent news
Headlines about TNGX (Tango Therapeutics, Inc.). Links open the publisher — we don’t host full articles.
-
William Blair Expands Biotech Research as Veteran Analyst Alethia Young Initiates Coverage
Yahoo Finance · 2026-10-21 -
TNGX Nov 2026 45.000 put (TNGX261120P00045000) stock price, news, quote and history
Yahoo Finance UK · 2026-10-21 -
Why Is Tango Therapeutics (NASDAQ:TNGX) Up 4.08% Before ESMO?
kalkine.ca · 2026-10-21 -
TNGX Nov 2026 20.000 call (TNGX261120C00020000) stock price, news, quote and history
Yahoo Finance UK · 2026-10-21 -
Tango Therapeutics (TNGX) Stock Looks Fully Valued After A 252% Run
Yahoo Finance · 2026-10-21 -
TNGX Nov 2026 20.000 call (TNGX261120C00020000) Stock Price, News, Quote & History
Yahoo! Finance Canada · 2026-10-21 -
TNGX Nov 2026 13.000 put (TNGX261120P00013000) Interactive Stock Chart
Yahoo! Finance Canada · 2026-10-20 -
TNGX Nov 2026 21.000 put (TNGX261120P00021000) Stock Price, News, Quote & History
Yahoo! Finance Canada · 2026-10-20
No headlines in this category right now — try “All”.